Effects of blocking of angiotensin system on the prevalence of metabolic syndrome in type 2 diabetic patients

Pakistan Journal of Medical Sciences

Volumn 29, Issue 1, 2012, Pages 140-143

  Mahmood, Isam Hamo ^a   Abed, Mohammed Najim ^a   Merkhan, Marwan Mohammed ^a  

^a UNIVERSITY OF MOSUL   (Iraq)

Author keywords

ACE inhibitors; ARBs; Metabolic Syndrome; Renin Angiotensin System; Type 2 diabetes mellitus

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; GLIBENCLAMIDE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; TELMISARTAN; TRIACYLGLYCEROL; VALSARTAN;

ADULT; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETIC HYPERTENSION; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PREVALENCE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

EID: 84930484517     PISSN: 1682024X     EISSN: None     Source Type: Journal    
DOI: 10.12669/pjms.291.2782     Document Type: Article

References (37)

1. Lusis AJ, Attie AD, Reue K. Metabolic syndrome: from epidemiology to systems biology. Nat Rev Genet. 2008;9(11):819-830.
2. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic Syndrome. Circulation. 2009;120:1640-1645.
3. Ninomiya JK, L'Italien G, Criqui MH. Association of the metabolic syndrome with history of myocardial infarction and stroke in the Third National Health and Nutrition Examination Survey. Circulation. 2004;109:42-46.
4. Stern L, Igbal N, Grundy SM. Metabolic Syndrome: A Multiplex Cardiovascular Risk Factor. J Clin Endocrinol Metab 2007;92:399-404.
5. Grundy SM. Metabolic Syndrome: A multiplex cardiovascular risk factors. J Clin Endocrinol Metab. 2007;92(2):399-404.
6. Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2496.
7. Morris RD, Rimm DL, Hartz AJ, Kalkhoff RK, Rimm AA. Obesity and heredity in the etiology of non-insulin-dependent diabetes mellitus in 32,662 adult white women. Am J Epidemiol. 1989;130:112-121.
8. Fatani HH, Mira SA, el-Zubier AG. Prevalence of diabetes mellitus in rural Saudi Arabia. Diabetes Care. 1987;10:180-183.
9. Prasad A, Quyyumi AA. Renin Angiotensin system and angiotensin receptor blockers in the metabolic syndrome. Circulation. 2004;110:1507-1512.
10. Velloso LA, Folli F, Sun XJ, White MF, Saad MJ, Kahn CR. Cross-talk between the insulin and angiotensin signaling systems. Proc Nalt Acad Sci. 1996;93:12490-12495.
11. De Kloet AD, Krause EG, Woods SC. The renin angiotensin system and the metabolic syndrome. Physiol Behav. 2010;100:525-534.
12. Engeli S. Role of the rennin-angiotensin aldosterone system in the metabolic syndrome. Contrib Nephrol. 2006;151:122-134.
13. Engeli S, Schling P, Gorzelniak K, Boschmann M, Janke J, Ailhaud G, et al. The adipose-tissue renin-angiotensin-aldosterone system: role in the metabolic syndrome. Int Biochem Cell Biol. 2003;35:807-825.
14. Stiefel P, Vallejo-Vaz A J, García Morillo S, Villar J. Role of The renin-Angiotensin System and Aldosterone on Cardiometabolic syndrome. Int J Hypertens. 2011; 685238 PMCID. PMC3139197.
15. Weisinger RS, Stanley TK, Begg DP, Weisinger HS, Spark KJ, Jois M. Angiotensin converting enzyme inhibition lowers body weight and improves glucose tolerance in C57BL/6J mice maintained on a high Fat diet. Physiol Behav. 2009;98:192-197.
16. Boustany CM, Bharadwaj K, Daugherty A, Brown DR, Randall DC, Cassis LA. Activation of the systemic and adipose renin-angiotensin system in rats with diet-induced obesity and hypertension. Am J Physiol Regul Integr Comp Physiol. 2004;287(4):R943-R949.
17. Schmieder RE, Hilgers KF, Schlaich MP, Schmidt BMW. Reninangiotensin system and cardiovascular risk. The Lancet. 2007;369(9568):1208.
18. Alderman MH, Madhavan S, Ooi WL, Cohen H, Sealey JE, Laragh JH. Association of the renin sodium profile with the risk of myocardial-infarction in patients with hypertension. N Eng J Med. 1991;324:1098-1104.
19. Engeli S, Negrel R, Sharma AM. Physiology and pathophysiology of the adipose tissue renin-angiotensin system. Hypertension. 2000;35:1270-1277.
20. Rahmouni K, Mark AL, Haynes WG, Sigmund CD. Adipose depot-specific modulation of angiotensinogen gene expression in diet-induced obesity. Am J Physiol Endocrinol Metab. 2004;286:E891-E895.
21. Van Harmelen V, Ariapart P, Hoffstedt J, Lundkvist I, Bringman S, Arner P. Increased adipose angiotensinogen gene expression in human obesity. Obes Res. 2000;8:337-341.
22. Yasue S, Masuzaki H, Okada S, Ishii T, Kozuka C, Tanaka T, et al. Adipose tissue-specific regulation of angiotensinogen in obese humans and mice: impact of nutritional status and adipocyte hypertrophy. Am J Hypertens. 2010;23:425-431.
23. Engeli S, Böhnke J, Gorzelniak K, Janke J, Schling P, Bader M, et al. Weight loss and the renin-angiotensin-aldosterone system. Hypertension. 2005;45:356-362.
24. Kalupahana NS, Moustaid-Moussa N. The renin-angiotensin system: A link between obesity, inflammation and insulin resistance. Obes Rev. 2012;13:136-149.
25. Braga MF, Leiter LA. Role of renin-angiotensin system blockade in patients with diabetes mellitus. Am J Cardiol. 2009;104:835-839.
26. Chu KY, Lau T, Carlsson PO, Leung PS. Angiotensin II type 1 receptor blockade improves beta-cell function and glucose tolerance in a mouse model of type 2 diabetes. Diabetes. 2006;55:367-374.
27. Goossens GH, Blaak EE, van Baak MA. Possible involvement of the adipose tissue renin-angiotensin system in the pathophysiology of obesity and obesity-related disorders. Obes Rev. 2003;4:43-55.
28. Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A, et al. Effect of angiotensin converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet. 1999;353:611-616.
29. Krutzfeldt J, Raasch W, Klein HH. Ramipril increases the protein level of skeletal muscle IRS-1 and alters protein tyrosine phosphatase activity in spontaneously hypertensive rats. Naunyn Schmiedebergs Arch Pharmacol. 2000;362:1-6.
30. Masuo K, Mikami H, Ogihara T, Tuck ML. Weight reduction and pharmacologic treatment in obese hypertensives. Am J Hypertens. 2001;14 (6 Pt 1):530-538.
31. Roncal CA, Reungjui S, Sánchez-Lozada LG, Mu W, Sautin YY, Nakagawa T, et al. Combination of captopril and allopurinol retards fructose-induced metabolic syndrome. Am J Nephrol. 2009;30:399-404.
32. Oksa A, Gajdos M, Fedelesova V, Spustova V, Dzurik RJ. Effects of angiotensin converting enzyme inhibitors on glucose and lipid metabolism in essential hypertension. Cardiovasc Pharmacol. 1994;23:79-86.
33. Derosa G, Cicero AF, D'Angelo A, Ragonesi PD, Ciccarelli L, Piccinni MN, et al. Telmisartan and irbesartan therapy in type 2 diabetic patients treated with rosiglitazone: effects on insulinresistance, leptin and tumor necrosis factor-alpha. Hypertens Res. 2006;29(11):849-856.
34. Sasaki T, Noda Y, Yasuoka Y, Irino H, Abe H, Adachi H, et al. Comparison of the effects of telmisartan and olmesartan on home blood pressure, glucose and lipid profiles in patients with hypertension, chronic heart failure and metabolic syndrome. Hypertension Research. 2008;31:921-929.
35. Kodama J, Katayama S, Tanaka K, Itabashi A, Kawazu S, Ishii J. Effect of captopril on glucose concentration. Possible role of augmented postprandial forearm blood flow. Diabetes Care. 1990;13:1109-1111.
36. Costa FV, Borghi C, Mussi A, Ambrosioni E. Hypolipidemic effects of long term anti hypertensive treatment with captopril. Am J Med. 1988;84:(Suppl 3A):159-161.
37. Chan JC, Yeung VT, Leung DH, Tomlinson B, Nicholls MG, Cockram CS. The effects of enalapril and nifedipine on carbohydrate and lipid metabolism in NIDDM. Diabetes Care. 1994;17:859-862.